ANPCF News and Press, Angle From 09/29/25

CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma Patients GBM CTC isolation only possible with Parsortix label-free methodology Data presented at the 7 th ACTC meeting GUILDFORD, SURREY / ACCESS Newswire / September 29, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-lead...

2025-09-09 08:59:24 ET ANGLE plc ADR (ANPCY) Q2 2025 Earnings Call September 9, 2025 6:00 AM EDT Company Participants Andrew David Newland - Founder, CEO & Executive Director Ian Griffiths - CFO, Finance Director, Company Secretary & Executive Director ... ...

ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 30 June 2025 COMMERCIALISATION PROGRESSED ACROSS MULTIPLE FRONTS DESPITE REVENUE PRESSURE FROM ADVERSE MARKET CONDITIONS Large pharma contracts completed successfully DNA Dual Analysis Illumina NGS assay...

APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical onc...

New publication in Nature Genetics using Parsortix identifies CTC clusters as promising targets to stop the spread of cancer GUILDFORD, SURREY / ACCESS Newswire / July 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell...

Result of 2025 Annual General Meeting GUILDFORD, SURREY / ACCESS Newswire / June 30, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. Details o...

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILING Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour heterogeneity in lung cancer patients GUILDFORD, SURREY / ACCESS Newswire / June 17, 2025 / ANG...

ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profiling Poster presentation highlights development of a novel CTC-based assay GUILDFORD, SURREY / ACCESS Newswire / June 17, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid ...

PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer Academic and translational research is the driving force behind the pipeline of next generation cancer therapeutics GUILDFORD, SURREY / ACCESS Newswire / June 10, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-le...

GUILDFORD, SURREY / ACCESS Newswire / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financi...